Certara Acquires Applied Biomath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies Blog Post
両社の統合によりライフサイエンス業界最大の定量的システム薬理学（QSP）支援体制が確立され、より迅速で効果的な医薬品開発に貢献します。Princeton, NJ – December 14th, 2023 ...
Answers to Drug Developers’ Frequent Electronic Common Technical Document Questions Blog Post
Although the Electronic Common Technical Document (eCTD) has been around for many years, it continues to evolve as the pharmaceutical industry adapts to changing regulatory standards and innovative technologies. DMDは小児疾...
Attain FDA Label Claims for Kinase Inhibitor Drugs with the Simcyp™ Simulator Blog Post
Simcyp was used by pharma and biotech companies to inform, reduce and/or replace clinical studies for 40 Kinase Inhibitor (KI) drugs.
Pharma Focus Europe – Issue 03 – Using AI to Accelerate Drug Development Blog Post
Authors: Professor Amin Rostami-Hodjegan, Professor Piet van der Graaf This Pharma Focus EU article, co-authored by Amin Rostami-Hodjegan, SVP of Research & Development and CSO at Certara, and Professor Piet…
Certara Launches Updated Version of Pirana Modeling Workbench Blog Post
PRINCETON, N.J.— 2023年12月1日 – Certara, Inc., a global leader in biosimulation, today announced the release of version 23.10.1 of Pirana, a workbench solution that simplifies and harmonizes the…
Creation of novel sensitive probe substrate and moderate inhibitor models for a comprehensive prediction of CYP2C8 interactions for tucatinib Blog Post
Authors: Ian E. Templeton, Karen Rowland-Yeo, Hannah M. Jones, Christopher J. Endres, Ariel R. Topletz-Erickson, Hao Sun, Anthony J. Lee A physiologically based pharmacokinetic (PBPK) model was developed to simulate plasma concentrations of tucatinib (Tukysa®) after…
Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development Blog Post
Simcyp Biopharmaceutics helps drug developers replace costly clinical bioequivalence studies and optimize formulations for complex therapies Princeton, NJ – November 21st, 2023 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader…
Key Lessons from the 2nd Annual FDA ASCO WORKSHOP on Getting the Dosage Right: Optimizing Dosage Selection Strategies in Combination Cancer Therapies Blog Post
Cancer treatment has evolved from generally cytotoxic therapies towards drugs that target specific pathways and alterations in cancer cells. Patients tolerate targeted therapies better, and their treatment continues over a…
The “Animal Rule” – What if a clinical trial simply isn’t ethical? Blog Post
Clinical trials always pose a challenge to demonstrating a drug’s safety and efficacy. Sometimes, the challenges are beyond difficult, presenting situations where it isn’t ethical or feasible to demonstrate efficacy…
